Not medical advice. The Journal of Biohacking reports published research and teaching models. Nothing on this page is medical advice, a diagnosis, or a recommendation to use any compound, product, or therapy. Where a dose appears, it is a figure reported in a cited study or by its sponsor, not an instruction. Editorial position on dosing.
Is there a cure for rheumatoid arthritis?
Every serious attempt to cure rheumatoid arthritis, graded on evidence rather than enthusiasm. The headline finding is uncomfortable and useful: not one peptide, including the much announced SenoMune-0257, has any human evidence in RA, while the first published drug-free remissions in refractory disease came from a cell therapy, CD19 CAR-T, in six patients in Berlin.
The verdict in numbers
This dossier applies one discipline throughout: only count evidence about the named product, in the named disease, in humans, with a control group or a hard endpoint. Press releases, mouse studies, and biomarker movements are labeled as what they are. Grades run A (human randomised trial) through B (early human), C (animal only), and D (press release or in vitro only), with a separate Negative grade for approaches humans have already tested and watched fail.
Case study: SenoMune-0257, or how a press release becomes a headline
In November 2026 a nine-amino-acid peptide was announced as a senolytic immunotherapy breakthrough, with arthritis and ageing language attached. It is the cleanest recent example of the gap this dossier exists to measure.
What actually happened
- Oct 12, 2026Immorta Bio announces completed preclinical studies: in the lab, the peptide stimulated cytotoxic T cells that killed senescent cells while sparing healthy cells, in the company's words, "under the conditions tested." No peer-reviewed paper on the peptide itself.
- Oct 29, 2026One patient with advanced cancer is dosed in Mexico, in an investigator-initiated study at Integrative Cancer Centers of America. The company supplied the peptide; independent investigators run the study.
- Nov 2, 2026The first-in-human release goes out. It states plainly that safety and efficacy "have not been established." It gives no dose, no patient count, no protocol, no endpoint, and no trial registry number.
- Registry checkSearching ClinicalTrials.gov for SenoMune or Immorta returns no registration at all, so there is no public protocol, eligibility criteria, or results obligation anyone can inspect.
What the citation actually supports
The releases lean on a peer-reviewed paper (Ichim et al., Journal of Translational Medicine 2025). Opened and read, that paper is about SenoVax, a different product: dendritic cells pulsed with senescent-cell lysate, tested only in mice with tumours. Not the peptide. Not arthritis. Not humans.
The mechanism itself is not nonsense. Senescent cells accumulate in RA joints, and training T cells to clear them works in mice (the uPAR CAR-T work, Nature 2020). But for this peptide the targeted antigen has never been publicly identified, and no arthritis experiment of any kind has been published.
Grade: D. For RA specifically, there is no evidence at all. Even on a flawless path, a first cancer dose in late 2026 sits roughly 7 to 12 years from any RA efficacy readout, and the senolytic field's powered-trial record in joints is currently 0 for 1.
Three tests of seriousness, all currently unmet: a public trial registration with a protocol; peer-reviewed data on SenoMune itself, not SenoVax; any stated RA programme with an arthritis model experiment.
The senolytic reality check
Clearing senescent "zombie" cells is the most marketed idea in this space. The biology and the clinical record point in opposite directions, and an honest dossier has to hold both.
The biology is real
- Senescent cells marked by p16 are increased prematurely in the joint lining of younger RA patients, compared with age-matched healthy tissue (Del Rey et al., 2019).
- Senescent joint fibroblasts overproduce exactly the inflammatory mediators that drive RA: IL-6, IL-8, and the tissue-degrading enzyme MMP-3.
- Senescent, tissue-invasive T cells also accumulate in RA joint tissue, part of the premature immune ageing documented in this disease.
- The honest caveat: inflammation itself drives cells into senescence, so senescence in RA may be an amplifier installed by the disease rather than its root cause.
The human record is not
UBX0101, the best-powered test of a senolytic inside a human joint, failed. In a randomised, double-blind Phase 2 in knee osteoarthritis, pain improvement at week 12 was indistinguishable from placebo at every dose:
Change in WOMAC pain score, week 12 (Lane et al., 2021). Dasatinib plus quercetin, the most studied senolytic pair, missed the primary endpoint of its largest randomised trial and has never been trialled in RA. Navitoclax clears senescent cells in dishes and mice but is dose-limited by platelet toxicity. Six years after the mouse uPAR CAR-T paper, no human senolytic immunotherapy trial has reported results in any disease.
The shortlist: four credible paths to durable remission
Ranked by evidence today, not by elegance. Everything not listed here, including every senolytic and every clinic peptide, failed to make this list for a stated reason in the explorer below.
CD19 CAR-T immune reset
The only approach with peer-reviewed, published drug-free remission in established, treatment-refractory RA. In the COMPARE Phase 1 (Nature Medicine, October 2026), six heavily pretreated patients stopped all RA drugs; three were in sustained remission with top-tier responses at up to about a year, autoantibodies collapsed, and repopulating B cells came back naive. A randomised Phase 2 against rituximab is now the most important trial in this field.
The catch · Six patients, one centre, seropositive disease only, chemotherapy conditioning first, cytokine release syndrome in all six, and one patient already relapsed at about week 44.
Checkpoint agonism and pathogenic T-cell depletion
Rosnilimab, an antibody that depletes PD-1-high pathogenic helper T cells, met its Phase 2b endpoints in 424 patients, with responses deepening to week 28 and holding at least 3 months after the last dose. That off-drug durability is the closest any non-cell therapy has come to reset-like behaviour. Peresolimab, a PD-1 agonist, proved the checkpoint concept in a randomised trial behind it (NEJM 2023).
The catch · Conference and press-release grade so far, no peer-reviewed paper yet, and 3 months off drug is not yet durability. Phase 3 is the test.
CAR-Treg therapy (SBT777101)
Regulatory T cells engineered to home to citrullinated proteins inside inflamed joints: suppression delivered to the joint rather than depletion of the whole system. The REGULATE-RA Phase 1 is recruiting in the United States now, and interim data in the first six patients showed no serious adverse events and joint count improvements in most by week 4, with joint biopsy evidence of local effect.
The catch · Six patients, company-reported, durability unknown. The biopsy and 6-month data are the near-term tell.
Antigen-specific tolerance, done early
The most intellectually credible peptide idea in the field: retrain only the response to joint antigens, without global immunosuppression. DEN-181, a liposomal collagen peptide plus calcitriol, is the best modern design, with a clean Phase 1 and real immune modulation. Interception data with abatacept in pre-RA prove the underlying point about timing: treatment before clinical disease delayed onset by years.
The catch · Twenty-five years, zero Phase 3 trials, and the largest trial in the class (dnaJP1, n = 160) missed its prespecified endpoint. This path belongs to early and pre-RA, not rescue of established disease.
The candidate explorer
All 27 candidates from the research report, filterable by evidence grade and by aim. One entry, LL-37, is deliberately absent: the report classifies it as not a candidate at all, because its own literature implicates it as a driver of autoimmunity. It appears in the red flags below instead.
What to watch, next 12 to 24 months
COMPARE Phase 2
CAR-T versus rituximab, head to head, in Berlin (NCT06475495). Enrolment and any interim data; registry completion is estimated in 2027. This trial answers whether deep tissue B-cell depletion beats the best existing B-cell therapy.
REGULATE-RA readout
The CAR-Treg Phase 1 (NCT06201416) completes around November 2026. Look for a peer-reviewed paper, not a release, with at least 6 months of durability and joint biopsy data.
Rosnilimab, paper and Phase 3
A peer-reviewed Phase 2b publication, and decisively, whether a Phase 3 launches. Peresolimab's Phase 3 decision at Lilly is the paired signal for the whole checkpoint class.
DEN-181 Phase 2, or silence
Any registry appearance of a multi-dose Phase 2 would make it the most credible peptide programme in RA. Continued absence through 2027 effectively confirms the programme is dormant.
Off-the-shelf CAR-T
The BMS allogeneic CD19 CAR-T Phase 1 (NCT07115745) is recruiting, including difficult-to-treat RA at US sites. Whether donor cells match autologous results decides how scalable the reset path becomes.
SenoMune seriousness tests
A public registration for the Mexico study, peer-reviewed data on the peptide itself, or any arthritis experiment. If none of the three appears, it remains a press-release platform, however the headlines read.
Red flags: the hype filter
Patterns that should end a conversation, drawn from how this market actually sells. One marketed peptide, LL-37, belongs here rather than in the explorer: the human literature implicates it in driving autoimmune inflammation, and clinic marketing of it for autoimmunity inverts its own evidence base.
Pay to participate
Legitimate trials do not charge participants for the investigational product. The FDA's consumer position is that patients charged to join a study outside an authorised trial are likely being deceived. A registry listing alone proves nothing; listings are borrowed for legitimacy.
Offshore dosing as a shortcut
Treating in a jurisdiction chosen for lighter oversight means no inspectable protocol, ethics review, manufacturing standard, or safety reporting, and no continuity of care if something goes wrong. The Mexico first dose of SenoMune is the archetypal structure.
Press-release-only science
A release that announces a dose given rather than a result, cites papers about different products, and names no registry number, dose, or endpoint is marketing, however accurate its individual sentences are.
One product, many diseases
Platforms marketed simultaneously for cancer, ageing, frailty, organ failure, and autoimmunity match the regulator profile of unproven-intervention marketing. Real therapies earn one indication at a time.
Surrogate-endpoint laundering
Falls in IL-6, anti-CCP antibodies, or T-cell percentages are hypothesis-generating, not results. RA history is full of immunologically beautiful, clinically empty outcomes; dnaJP1's missed primary endpoint is the canonical example.
Invented trials and cure language
During this research, search results surfaced a content-farm article crediting a fictitious company with a Phase 3 gene therapy achieving over 90 percent sustained remission in RA. No such trial exists. A claim that size would be in a major journal and on a registry within days. Check there first.
Verify any claim in 10 minutes
- Find the registry number. Open the NCT, ISRCTN, or ANZCTR record: sponsor, phase, patient count, primary endpoint, status, and the results tab. No number, no trial.
- Read the paper, not the release. Check whether the prespecified primary endpoint was met, not a post-hoc subgroup or a completer analysis.
- Check the approval databases. Search FDA and EMA listings for the product name before believing any availability claim.
- Ask who is running it. A university rheumatology centre with a registry record, or a clinic selling the treatment? The second answer ends the inquiry.
- Ask what it costs the participant. In a legitimate interventional trial, the study drug costs the participant nothing.
What is not supported by evidence
Stated plainly, so nobody has to guess
- No peptide cures RA, and none has been shown to induce drug-free remission in RA. Not one.
- SenoMune-0257 has no demonstrated safety or efficacy in any human for any condition, no published data as a peptide, and no connection to RA in any experiment or trial.
- Senescent-cell clearance has never improved a human joint outcome in a controlled trial. The best-powered test, UBX0101, failed.
- No antigen-specific tolerogenic therapy has ever passed a Phase 2 primary endpoint cleanly in RA, and none has entered Phase 3.
- CAR-T drug-free remission in RA is proven possible, not proven general: 3 of 6 patients, under one year, one centre, with chemotherapy conditioning. Long-term safety is unknown.
- Nothing prevents RA outright. The best interception data, abatacept in pre-RA, show delay measured in years, with a waning effect.
- No supplement, compounded peptide, senolytic cocktail (including dasatinib plus quercetin and fisetin), or offshore clinic programme has controlled-trial evidence of benefit in RA.